Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14176MR)

This product GTTS-WQ14176MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14176MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6468MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4194MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ2500MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ5763MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ2369MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ8047MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ13440MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW